About UsNewsShop
Fighting hereditary breast and ovarian cancer
Information & Research
| More

NCT00892736

ABT-888 (Veliparib) in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy

Study identifier: NCT00892736
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Veliparib (Abbott)

Eligibility:

  • Documented BRCA1/2 mutation AND a BRCA-related malignancy (e.g., primarily
    breast or ovarian cancer, but may include prostate or pancreatic cancer). Progressive disease after standard therapy OR no acceptable standard treatment options available.

Type of study:

Phase I

Treatment:

  • Patients receive oral ABT-888 twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or toxicity.

Study site:

Pennsylvania

UPMC Cancer Center
Pittsburgh, Pennsylvania, 15232
Contact: Clinical Trials Office - UPMC Cancer Centers     412-647-8073  

 

Page updated 03/21/11


Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.

Privacy Policy | Sitemap | Contact Us

Morphtek

This site has been made possible by a generous grant from Morphotek.


Web design by Rareheron Web Design

copyright © FORCE: Facing Our Risk of Cancer Empowered, Inc.  •  info@facingourrisk.org